ALK and lung carcinoma: Although several kinase inhibitors are clinically utilized to treat oncogenic kinase fusion-positive cancer (e.g., ALK inhibitor to treat ALK fusion-positive lung cancer), at present29, acquired resistance to kinase inhibitors has become a problem in clinical practice.